Aleglitazar – an Upcoming Dual Ppar Alpha/gamma Agonist in Reducing the Macro Vascular Risks Associated with Type 2 Diabetes Mellitus
نویسنده
چکیده
Diabetes is a chronic disorder frequently associated with failure of vital organs like eyes, heart,kidneys, nerves, and blood vessels. Treatment of diabetic complications with drugs was classified as monotherapy, dual therapy and triple therapy. Many patients cannot obtain satisfactory glycemic control with current therapies, and eventually develope micro vascular and macro vascular complications. New and more effective agents targeted for therapy are required.This review focuses on the therapeutic potential of novel dual PPAR alpha/gamma agonist ,aleglitazar in comparision with PPARγ agonists.Aleglitazar exerts dual effects in lowering plasma triglycerides and increasing HDL cholesterol and is the first target for reducing cardiovascular risk among Glitazars. Further studies are needed to provide benefits of cardiovascular events and changes in long term lipid profiles.
منابع مشابه
Advisory Committee Briefing Document Preclinical Pharmacology and Toxicology Summary Drug: Pargluva® (muraglitazar, BMS-298,585) Drug class: Peroxisome Proliferator-Activated Receptor dual agonist Clinical Indication: Type 2 diabetes
The peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that regulate gene expression in response to ligand binding. Three PPAR receptor subtypes, namely gamma, alpha and delta (beta), have been identified. The development of PPAR agonist pharmaceuticals for the treatment of type 2 diabetes, dyslipidemia, and obesity is currently an area of great interest. The FDA has recei...
متن کاملSelective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Dyslipidemia is a major risk factor for cardiovascular (CV) disease - the primary cause of death, worldwide. Although reducing levels of low-density lipoprotein-cholesterol can significantly reduce CV risk, a high level of residual risk persists, especially in people with obesity-related conditions, such as metabolic syndrome and type 2 diabetes mellitus. Peroxisome proliferator-activated recep...
متن کاملMedicinal Chemistry and Actions of Dual and Pan PPAR Modulators
Peroxisome proliferator-activated receptor (PPAR) agonists are used as adjunct therapy in the treatment of diabetes mellitus. Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, and clofibrate act on PPAR alpha to reduce the level of hypertriglyceridemia. However, agonists (ligands) of PPAR-beta/delta receptors, such as tesaglitazar, muraglitazar, ragaglitazar, imiglitazar...
متن کاملThe cardiovascular effects of peroxisome proliferator-activated receptor agonists.
Although peroxisome proliferator-activated receptor agonists are prescribed to improve cardiovascular risk factors, their cardiovascular safety is controversial. We therefore reviewed the literature to identify landmark randomized controlled trials evaluating the effect of peroxisome proliferator-activated receptor gamma agonists (pioglitazone and rosiglitazone), alpha agonists (fenofibrate and...
متن کاملComparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors that control the expression of genes involved in a variety of physiologic processes, through heterodimerization with retinoid X receptor and complex formation with various cofactors. Drugs or treatment regimens that combine the beneficial effects of PPARα and γ agonism present an attractive therapeutic...
متن کامل